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Guideline Compliance in the Management of Patients 
with Unstable Angina/Non-STEMI without PCI Procedure 
(Medically Managed Registry)
Erwinanto , Angke Widya, Nahar Taufik, Sri Diniharini, Dolly Kaunang, Arini Setiawati
Aim: To document current usage of antiplatelet therapy and the implemen-
tation of ACC/AHA 2007 guideline in the clinical management of unstable 
angina/ non-ST-elevation myocardial infarction (UA/NSTEMI) patients not 
undergoing PCI procedure in Indonesia (medically managed) and their risks 
according to Global Registry of Acute Coronary Events (GRACE) score as 
well as in-hospital mortality. 
Method: A multicenter observational, prospective disease registry, recruit-
ing patients with UA/NSTEMI. No specific treatment will be recommended 
in this disease registry. Data will be collected based on Physician’s applicable 
daily practices without any intervention.
Results: A total of 467 eligible patients, 246 patients with UA and 221 
with NSTEMI, aged 18 years or older were recruited from 18 hospitals 
during December 2009 – January 2011. Most recruited patients were at 
low risk (63.9%) and only 0.9% patients were at high risk according to the 
GRACE score. Patients were treated with ASA (90.6%) and Clopidogrel 
(96.6%) when they reached the emergency department. Medical therapy 
instituted during hospitalization were injectable anticoagulant (91.4%), oral 
anticoagulant (0.9%), oral nitrate (82.7%), beta blocker (60.8%), ACE 
inhibitor (49%), angiotensin receptor blocker (20.3%), calcium channel 
blocker (19.9%), statin (13.1%), and other medications given according 
the presentation of complications or comorbidities. In-hospital mortality 
was documented in 3.2% of patients. At discharge ASA was given to 87.6% 
and clopidogrel to 94.2% patients. 
Conclusion: The result showed that most of the patients admitted with 
UA/NSTEMI were at low or moderate risk according to GRACE score. 
Although treatment with antiplatelet and anticoagulant largely followed the 
ACC/AHA guidelines, however, this registry documented under treatment 
of other medications such as ACE-inhibitors and beta blockers. Reinforce-
ment of the guideline compliance and continuous medical education would 
provide better outcomes for the patients. 
(J Kardiol Indones. 2015;36:130-7)
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Tujuan: Registri ini utamanya bertujuan melakukan dokumentasi terhadap pasien yang mendapatkan terapi antiplatelet dan 
implementasi pedoman tatalaksana klinis dari ACC/AHA bagi pasien angina tidak stabil/infark miokard tanpa elevasi segmen 
ST yang tidak menjalani terapi reperfusi di Indonesia (Medically Managed Registry). Tujuan tambahan adalah mengetahui 
tingkat risiko pasien berdasarkan Global Registry of Acute Coronary Events (GRACE) dan tingkat kematian selama perawatan 
di rumah sakit.
Metodologi: Registri prospektif dan multi-senter dengan cakupan pasien yang telah terdiagnosis angina tidak stabil/infark 
miokard tanpa elevasi segmen ST yang tidak menjalani terapi reperfusi. Registri ini tidak merekomendasikan intervensi apapun. 
Data dicatat sesuai praktik dokter yang merawat.
Hasil: Dari 18 rumah sakit di Indonesia, selama periode Desember 2009 sampai dengan Januari 2011, tercatat 467 pasien 
yang mempunyai kesesuaian dengan inklusi dan eksklusi, terdiri dari 246 pasien dengan angina tidak stabil dan 221 pasien 
dengan infark miokard tanpa elevasi segmen ST. Sebagian besar (63,9%) pasien mempunyai risiko rendah dan hanya 0,9% 
berisiko tinggi sesuai kriteria GRACE. Sebanyak 90,6% pasien mendapat terapi ASA dan 96,6% mendapat terapi clopidogrel 
saat dirawat di ruang gawat darurat. Terapi medikal yang diberikan selama perawatan rumah sakit adalah sebagai berikut: an-
tikoagulan intravena (91,4%), antikoagulan oral (0,9%), preparat nitrat oral (82,7%), penyekat beta (60,8%), inhibitor ACE 
(49%), penyekat reseptor angiotensin (20,3%), calcium channel blocker (19,9%), statin (13,1%), dan obat lain sesuai komplikasi 
dan penyakit penyerta. Dari seluruh pasien, tercatat 3,2% meninggal selama perawatan rumah sakit. Terdapat 6,3% dari pasien 
dengan diagnosis infark miokard dan 0,4% dari pasien dengan diagnosis angina tidak stabil meninggal selama perawatan rumah 
sakit. Terapi antiplatelet yang diberikan saat meninggalkan rumah sakit adalah ASA (87,6%) dan clopidogrel (94,2%).
Kesimpulan: Sebagian besar pasien mempunyai risiko rendah dan menengah berdasarkan kriteria GRACE. Sebagian besar pasien 
mendapatkan terapi antiplatelet yang dianjurkan oleh pedoman ACC/AHA. Registri ini mencatat sedikit pasien mendapatkan 
pengobatan seperti penyekat beta dan inhibitor ACE.  Diperlukan usaha meningkatkan ketaatan menggunakan terapi medikal 
yang dianjurkan oleh pedoman tatalaksana pengobatan melalui pendidikan berkelanjutan.
(J Kardiol Indones. 2015;36:130-7)
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Introduction
The GRACE risk score is a simple, robust tool for predicting in-hospital mortality in patients with acute coronary syndrome (ACS) and can be useful to assist in decision 
making with regard to treatment options in patients 
with ACS.1 Invasive strategy is preferred for patients 
with high risk score and conservative strategy is 
preferred for those with low risk score.
The ACC/AHA (American College of Cardiol-
ogy/American Heart Association) 2007 guideline 
recommendations reflect a consensus of expert opinion 
following a thorough review of late-breaking clinical 
trials deemed to have an impact on patient care. The 
guidelines attempt to define practices that meet the 
needs of most patients in most circumstances. The writ-
ing group of several guidelines continues to emphasize 
the importance of giving consideration for the use of 
cardiovascular medications that have been proven in 
randomized clinical trials to be of benefit. 
Some medications such as ASA, clopidogrel, 
injectable anticoagulant, beta blocker, ACE inhibitor or 
angiotensin receptor blocker, and statin when given to 
patients with UA/NSTEMI have been associated with 
improvement in cardiovascular morbidity and mortality 
and therefore included into class I medications.
Despite the growing number of hospitals with ability 
to perform percutaneous coronary intervention (PCI) in 
Indonesia, the total numbers of such hospitals are still 
limited. Most patients with UA/NSTEMI are predicted 
to be still treated medically irrespective of their GRACE 
risk score. Current data in Indonesia about guidelines 
compliance of patients treated medically are usually 
derived from single center or hospital.
The primary objective of this study is to document 
current usage of antiplatelet therapy and the implementa-
tion of ACC/AHA guideline in the clinical management 
of UA/NSTEMI patients without PCI procedure in 
Indonesia (Medically Managed Registry). The secondary 
objectives are to explore the UA/NSTEMI patients in In-
donesia from their demographic data, risk level according 
to GRACE score, and to detect in-hospital mortality.
Methods 
Study design
This was a multicentre, observational, prospective 
disease registry. The primary objectives of this study 
are to assess current usage of antiplatelet therapy and 
ACC/AHA2007 guideline in the clinical management 
of unstable angina/ non-ST-elevation myocardial 
infarction (UA/NSTEMI) patients not undergoing 
PCI procedure in Indonesia. Secondary objectives are 
to describe the demographic data of UA/NSTEMI 
patients in Indonesia and to assess risks of patients 
according to GRACE score.
To document current usage of antiplatelet therapy 
and the implementation of ACC/AHA 2007 guideline 
in the clinical management of unstable angina/ non-
ST-elevation myocardial infarction (UA/NSTEMI) 
patients not undergoing PCI procedure in Indonesia 
(medically managed) and their risks according to 
Global Registry of Acute Coronary Events (GRACE) 
score as well as in-hospital mortality.
 
Study patients
Study participants were recruited consecutively from 
18 centers (10 centers have coronary intervention 
facility) in Indonesia. Patients with UA/NSTEMI 
(positive chest pain and ST segment depression 
and/or T wave inversion with or without elevated 
of troponin or CKMB), not planned for invasive 
procedure at the time of diagnosis, aged 18 years or 
older, and were willing to sign informed consent form 
were eligible to be included in this study.  Pregnant or 
breast-feeding women and patients who participated 
in other clinical study were excluded from the study. 
The study was started in December 2009 and ended 
in January 2011.
Study procedure
Patients were treated according to the physician daily 
practices without any intervention from the investiga-
tor. Data were recorded in the DCF (Data Collection 
Form) for each patient during hospitalization. Data 
were gathered on: demographic, risk factors, medical 
management, duration of hospital stay, in-hospital 
mortality, and left ventricular systolic function.
Statistical analysis
Descriptive statistics were used. Continuous variables 
were summarized as mean, standard deviation, median 
and range. Nominal variables were summarized as 
frequencies and percentages. The analysis is planned 
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to describe at baseline subject characteristics, including 
risk factors, atherothrombotic disease and anti platelet 
therapies. No comparison analysis will be made
The study was conducted after approval by local 
ethic committee.
Results
A total of 467 UA/NSTEMI patients not selected for 
invasive procedure at the time of diagnosis, consist of 
246 (52.7%) with unstable angina and 221(47.3%) 
with NSTEMI, were recruited from 18 participating 
centers from December 2009 to January 2011.
Baseline characteristics were shown in Table 1. 
Mean age was 58.6 years and more than 60% of the 
patients were males. Among 47% of patients who 
have their left ventricular ejection fraction (LVEF) 
measured during hospitalization, 20.6% have LVEF 
less than 40%.  Hypertension was the most frequent 
documented risk factor. About 60% of patients reached 
the emergency department before 12 hours from the 
onset of ACS (see Table 2). 
During hospitalization, diagnostic angiography 
procedures were performed in 89  patients (19.1%) 
at 3 – 4 days after admission and 57 of them (12.2%) 
underwent PCI. Average  duration of the hospital stay 
was 6 to 7 days, which was 2-3 days longer in those 
who underwent PCI during hospitalization. 
There were 15 patients (3.2%) who died during 
hospitalization. These consisted of 12 patients (2.9%) 
in the medical treatment group and 3 patients (5.3%) 
among those who underwent PCI, leaving 452 patients 
alive at the end of the study. In-hospital mortality of 
patients admitted with unstable angina was 0.4% 
compared with 6.3% of those with NSTEMI.
Data of antiplatelet treatment during hospitaliza-
tion was not available in 4 patients. Table 4 shows 
that dual antiplatelet therapy, aspirin and clopidogrel, 
were given to 89.2% of patients. Patients treated with 
aspirin alone or clopidogrel alone were 2.2% and 
8.6% respectively. Medical treatment group  treated 
with clopidogrel received a loading dose of 300 mg in 
373/467 (80%) and 600 mg in only 4/467 patients 
(0.9%). An aspirin loading dose of 160 mg and 320 
mg were given to 45% and 28% of patients who were 
treated with aspirin respectively.   
Table 4 shows anticoagulant treatment during 
Table 1. Patients’ baseline characteristics            
Total Unstable Angina (UA) NSTEMI
(N= 467) (N = 246) (N = 221)
Age (yrs) : mean (SD) 58.6 (10.52) 58.2 (9.82) 59.0 (11.26)
Males: n (%) 305 ( 65.3%) 157 (63.8%) 148 (67.0%)
LVEF measurements: n (%) 218 (47.0%) 114 (46.3%) 104 (47.1%)
Ejection fraction < 40% 45 (20.6) 25 (21.9) 20 (19.2)
Risk factors : n (%)
1. Hypertension 298 (63.8) 169 (68.7) 129 (58.4)
2. Smoking 170 (36.4) 82 (33.3) 88 (39.8)
3. Dyslipidemia 164 (35.1) 85 (34.6) 79 (35.7)
4. Diabetes mellitus 115 (24.6) 59 (24.0) 56 (25.3)
5. Early CHD in the family 20 (4.3) 10 (4.1) 10 (4.5)
6. Chronic kidney failure 12 (2.6) 4 (1.6) 8 (3.6)
7. Stroke/TIA 11 (2.4) 6 (2.4) 5 (2.3)
8. Age > 55 years 281 (60.2) 145 (58.9) 136 (61.5)
9. PVD 1 (0.2) 1 (0.4) -
CHD: coronary heart disease, TIA: transient ischemic attack, PVD: peripheral vascular disease
Table 2. Onset of ACS 
 Total Unstable Angina (UA) NSTEMI
 (N= 467) (N = 246) (N = 221)
NSTEACS onset (%)
< 12 hrs 61.0% 61.8% 60.2%
12 - < 24 hrs 18.2% 14.2%        22.6%
24 - 72 hrs 18.2% 21.5%       14.5%
> 72 hrs   1.5%  1.6%                1.4%
not available   1.1%   0.8%   1.4%
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hospitalization. There were 51 patients who have their 
anticoagulant treatment not recorded. Most of the 
patients (46.9%) received enoxaparin for 4 – 5 days. 
Unfractionated heparin and fondaparinux was given 
for 3 and 4 – 5 days respectively.
More patients were treated with oral nitrates than 
with beta-blockers or ACE-inhibitors (see Table 5). 
Statins were given to less than 15% of patients. Diuretics 
(furosemide) were given to those with heart failure.
GRACE score could be evaluated in 454 patients. 
Low to moderate GRACE score were detected in about 
99% of patients (see Table 6). GRACE risk score 
was higher among the patients with NSTEMI than 
unstable angina. 
Discussion
Medically Managed Registry is a multicentre registry 
performed in 18 hospitals in Indonesia during 
December 2009 to January 2011 where 10 of 
these hospitals have the ability to perform coronary 
intervention. The mean age of patients in this registry 
were 58.6 years and this is almost similar with the age 
reported in South East Asia and Japan acute myocardial 
infarction study (57 years) but somehow younger than 
study from China and Hong Kong (63 years).2 Patients 
recruited in this registry were also younger than that 
reported in the GRACE model.3 
Left ventricular ejection fraction is an independent 







Aspirin + Clopidogrel 413 (89.2%) 214 (87.4%) 199 (91.3%)
Aspirin alone 10 (2.2%)     5 (2.0%)     5 (2.3%)
Clopidogrel alone 40 (8.6%)   26 (10.6%)   14 (6.4%)







UFH   80 (17.1%)    41 (18.9%)   39 (19.6%)
Enoxaparin 235 (46.9%) 123 (56.7%) 112 (56.3%)
Fondaparinux 101(21.4%)   53 (24.4%)   48 (24.1%)
UFH: unfractionated heparin







1. Oral nitrates 386 (82.7) 203 (82.5) 183 (82.8)
2. Beta blockers 284 (60.8) 144 (58.5) 140 (63.3)
3. ACE inhibitors 229 (49.0) 115(46.7) 114 (51.6)
4. Diuretics 135 (28.9) 60(24.4) 75 (33.9)
5. Angiotensin receptor blockers 95 (20.3) 50 (20.3) 45 (20.4)
6. Calcium channel blockers 93 (19.9) 46 (18.7) 47 (21.3)
7. Statins 61 (13.1) 27 (11.0) 34 (15.4)
Table 6. GRACE Risk Score 
   Total Unstable Angina (UA) NSTEMI
 (N= 454)  (N = 236)    (N = 218)
Low ( < 100) 290 (63.9%) 165 (67.1%) 125 (56.6%)
Medium (100 – 149) 160 (35.2%)   70 (28.5%)   90 (40.7%)
High (> 150)     4 ( 0.9%) 1 (  0.4%)   3 ( 1.4%)
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predictor of mortality and other major adverse cardiac 
events in UA/NSTEMI. Among 47% of patients who 
have their LVEF measured during hospitalization, 
20.6% have LVEF less than 40%. This result might 
have some clinical implications.  Invasive strategy is 
generally preferred for patients with low LVEF (≤ 
40%).4,5,17 Angiotensin converting enzyme (ACE) 
inhibitors and angiotensin receptor blockers (ARBs) 
are well established in secondary prevention6,7 and 
are especially indicated for patients with reduced LV 
function. Beta-blockers are also recommended in all 
patients with reduced LV systolic function.
In this study hypertension was detected in 63.8% 
of patients which was the highest amongst all risk 
factors, followed by smoking, dyslipidemia, and 
diabetes. In the Global Registry of Acute Coronary 
Events (GRACE), prior or current smoking and 
hypertension were present as risk factors in more than 
half of the patients. Approximately 45% of patients 
had a diagnosis of hyperlipidemia and less than 25% 
had diabetes mellitus.3 The INTERHEART study 
suggested the risk of myocardial infarction (MI) 
attributable to hypertension and other risk factors 
like smoking, lipids, diabetes, abdominal obesity, 
and the combined psychosocial index is likely to be 
similar across most region of the world, including 
Asia.2 The INTERHEART study recorded 15% of 
MI was attributed to hypertension. The burden of 
MI associated to hypertension in South-east Asia and 
Japan was the highest among all regions, much higher 
than that in South Asia and China. The reason for this 
is identifiable by the high prevalence of hypertension 
in Japan and some region in South-East Asia such as 
Indonesia. Therefore, it has been suggested that the 
overall approach to the prevention of MI attributed 
to hypertension could be similar worldwide, but with 
varying emphasis in geographic region on the basis of 
the prevalence of hypertension. National hypertension 
prevalence for person aged over 15 years was 29.8% 
and only 24% of them were aware of the diagnosis.8 
Around 60% of the patients in this registry 
reached emergency department before 12 hours from 
the onset of ACS. Focus groups conducted for the 
REACT research program9,10 revealed that patients 
commonly hold a preexisting expectation that a heart 
attack would present dramatically with severe, crushing 
chest pain, such that there would be no doubt that one 
was occurring. Other published reasons for any delays 
were that patients thought their symptoms were self-
limiting and would go away or were not serious.11,12 
As a comparison, the Thai Acute Coronary Syndrome 
Registry (TACSR) observed the median time from the 
onset of the episode of chest pain to admission was 
6.0 hours.13 The OPERA registry in France observed 
the median time between symptom onset and arrival 
at hospital was 6 hours and was shorter in patients 
with STEMI vs. those with NSTEMI (4 vs. 7 hours, 
P < 0.0001).14
Variables such as age, heart rate, systolic blood 
pressure, serum creatinine level, Killip class at 
admission, presence of ST-depression, and elevated 
cardiac biomarkers as well as cardiac arrest are included 
in the calculation of GRACE MODEL.1 In this 
registry, low to moderate GRACE risk score were able 
to stratified in about 99% of patients in this registry. 
GRACE risk score was found to be higher among 
patients with NSTEMI than those with unstable 
angina. Patients with high GRACE score in this study 
might have undergone PCI considering that 10 out 
18 participating hospitals have the ability to perform 
coronary intervention. During hospitalization, 57 
patients (12.2%) underwent PCI 3 – 4 days after 
admission. 
The in-hospital mortality rate in low and 
intermediate risk categories according to the GRACE 
risk score is less than 1% and 1 – 3% respectively.1 
Hospital mortality in this registry was 3.2%, which 
was higher among patients who underwent PCI 
(5.3%) compared to those in the medical treatment 
group. This showed that patients who underwent PCI 
during hospitalization have a higher risk than those 
who did not. As a comparison, in-hospital mortality 
of patients admitted with non-ST-elevation ACS 
from 2002 to 2005 was as high as 9.5% in the Thai 
Acute Coronary Syndrome Registry (TACSR) 13. In-
hospital mortality in this registry was 0.4% and 6.3% 
in patients admitted for unstable angina and NSTEMI 
respectively, which was lower than that observed in the 
Acute Coronary Syndrome (ACS) Registry in Malaysia 
(3% for unstable angina and 7% for NSTEMI).  
This registry showed that most of the patients 
were treated with antiplatelets according to current 
guidelines.4,5,17 Almost 90% of the patients received a 
combination of aspirin and clopidogrel. A loading dose 
of 300 mg clopidogrel was given to 94 % of medical 
treatment patients and a loading dose of 160 mg to 320 
mg aspirin was also given to 91% of these patients. 
In the CURE trial (Clopidogrel in Unstable 
Angina to Prevent Recurrent Events), a clopidogrel 
hydrogen sulfate 300 mg loading dose followed by 75 
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mg daily maintenance for 9 – 12 months in addition 
to aspirin could reduce the incidence of cardiovascular 
death and non-fatal MI or stroke by 20% compared 
with aspirin alone.16 The study suggests that a delay of 
even one day in initiating clopidogrel after the onset of 
symptoms of ACS exposes a patient to a significant risk 
of cardiovascular death, myocardial infarction, stroke 
and severe ischemia. In this study some patients were 
treated with aspirin or clopidogrel alone. 
Current data from this registry showed that 
clopidogrel data was not available to all patients and 
some doctors tend to avoid aspirin therapy for patients 
with a history of aspirin intolerability when these 
patients were hospitalized with diagnoses of ACS. 
All patients were receiving injectable anticoagulants 
as recommended by guidelines. Almost half of the 
patients were treated with enoxaparin which was twice 
higher than those treated with fondaparinux. Only 
17.1% of patients were treated with unfractionated 
heparin. 
More than 80% of patients received oral nitrates. 
The use of nitrates in unstable angina is largely based 
on pathophysiological considerations and clinical 
experience. There are no randomized placebo-
controlled trials to confirm efficacy of this class of 
drugs in reducing risk of major adverse cardiac events. 
Guidelines recommend the use of medications that 
have been established in reducing risk of major adverse 
cardiac events such as ACE-inhibitors, beta blockers, 
and statins. ACE inhibitors or ARBs are well established 
in secondary prevention and are especially indicated in 
patients with reduced LV function. Oral beta-blockers 
are indicated for ACS patients with concomitant 
tachycardia, hypertension, or LV dysfunction. Statin 
therapy with target LDL-C levels <70 mg/dL initiated 
early after admission is recommended. 
Data from this registry showed that patients with 
ACS in this study were under treated with ACE-
inhibitors (or ARBs), beta blockers, and especially 
statins. Efforts need to be done to implement these 
drugs to more patients in order to reduce cardiac 
events.
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